Abstract
In 2008, the combined Asia Pacific Biomaterials market was worth $810.2
million. This study of the orthopedic biomaterials markets in Australia,
Japan, South Korea and China covers autograft, bone graft substitutes
(allograft, DBM and synthetic), hyaluronic acid viscosupplementation, and bone
morphogenic growth factor therapy. In each country, the different segments are
analyzed by units, procedure numbers and average selling price.
|